| Q48095393 | A cognitive-neuroscience approach for elucidation of mechanisms underlying temporal information processing |
| Q48025123 | A nanogram dose of the CYP3A probe substrate midazolam to evaluate drug interactions. |
| Q101155836 | A simple decision tree suited for identification of early oral drug candidates with likely pharmacokinetic nonlinearity by intestinal CYP3A saturation |
| Q30498467 | Auditory and electroencephalographic effects of midazolam and alpha-hydroxy-midazolam in healthy subjects |
| Q36110529 | CYP3A-dependent drug metabolism is reduced in bacterial inflammation in mice |
| Q47367892 | Clarithromycin, Midazolam, and Digoxin: Application of PBPK Modeling to Gain New Insights into Drug-Drug Interactions and Co-medication Regimens |
| Q90454566 | Comparison of intranasal versus intravenous midazolam for management of status epilepticus in dogs: A multi-center randomized parallel group clinical study |
| Q49067894 | Dopamine-antagonistic, anticholinergic, and GABAergic effects on declarative and procedural memory functions |
| Q34677362 | Dose equivalence of midazolam and triazolam. A psychometric study based on flicker sensitivity, reaction time and digit symbol substitution test |
| Q51792052 | Dose-finding and pharmacokinetic study of intramuscular midazolam. |
| Q48588616 | Effect of the treatment period with erythromycin on cytochrome P450 3A activity in humans |
| Q51764721 | Effects of age, gender and oral contraceptives on intramuscular midazolam pharmacokinetics. |
| Q44600105 | Genotype???phenotype associations for common CYP3A4 and CYP3A5 variants in the basal and induced metabolism of midazolam in European- and African-American men and women |
| Q44247783 | Human variability in CYP3A4 metabolism and CYP3A4-related uncertainty factors for risk assessment |
| Q51452446 | Intraindividual variability in male hepatic CYP3A4 activity assessed by alfentanil and midazolam clearance. |
| Q51562990 | Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. |
| Q42659971 | Midazolam: kinetics and effects on memory, sensorium, and haemodynamics |
| Q39669506 | New intravenous anaesthetics and neuromuscular blocking drugs. A review of their properties and clinical use. |
| Q51512697 | Pharmacokinetic-pharmacodynamic modeling of the coexistence of stimulatory and sedative components for midazolam. |
| Q51564998 | Pharmacokinetics and bioavailability of midazolam after intravenous, subcutaneous, intraperitoneal and oral administration under a chronic food-limited regimen: relating DRL performance to pharmacokinetics. |
| Q35803814 | Pharmacokinetics and pharmacodynamics of midazolam administered as a concentrated intranasal spray. A study in healthy volunteers |
| Q43501441 | Pharmacokinetics of midazolam in children: comparative study of intranasal and intravenous administration |
| Q38353433 | Pharmacokinetics of the newer benzodiazepines |
| Q35825212 | Phenotyping CYP3A using midazolam in cancer and noncancer Asian patients |
| Q34384341 | Predicting the impact of physiological and biochemical processes on oral drug bioavailability |
| Q38346576 | Premedication for upper gastrointestinal endoscopy |
| Q41737190 | Safety and pharmacokinetics of the CIME combination of drugs and their metabolites after a single oral dosing in healthy volunteers. |
| Q44074576 | Sedation induced by midazolam in intensive care: pharmacologic and pharmacokinetic aspects |
| Q39476375 | The Prediction of the Relative Importance of CYP3A/P-glycoprotein to the Nonlinear Intestinal Absorption of Drugs by Advanced Compartmental Absorption and Transit Model |
| Q51760565 | The pharmacokinetics of midazolam in paediatric patients. |
| Q34398445 | The pharmacokinetics of midazolam in patients with congestive heart failure |
| Q43836988 | The single-dose pharmacokinetics of midazolam and its primary metabolite in pediatric patients after oral and intravenous administration |